Facebook
Messenger
Twitter
LinkedIn
Email
Print
Monoclonal Antibodies: Update on COVID-19 Experimental Therapy
Share this:
Current experimental treatments for COVID-19 focus on two targets: the virus or the immune system. On the immune system side, the number of experimental treatments is growing. The vast majority are called monoclonal antibodies.
This type of drug is not new, and many are currently approved to treat conditions such as cancer or rheumatoid arthritis. But some are being developed from scratch to boost the initial immune response for patients who are at risk of severe COVID-19 disease.
These experimental drugs may provide patients with a way to get ahead of the virus and help manage the strain on hospital intensive care services. But what are monoclonal antibodies?
Read more about this crucial tool in the fight against COVID-19 in Discovery's Edge, Mayo Clinic's research magazine offering insight into the process and progress of medical science at the world's largest group medical practice.
Make a gift now to help transform the future of health care today.
Growing up in the Dominican Republic, Johanny Lopez Dominguez remembers her grandfather's health struggle. He lived in a remote part of the country, and it was challenging to get the care he needed for his diabetes and cardiovascular disease, resulting in many complications. A spot of hope was a physician who periodically traveled several miles to care for her grandfather.
I wanted to do something unique for my high school senior project in Windom, Minnesota. So when it came time to brainstorming ideas, I knew [...]
According to family legend, Joan Arndt was 3 years old when she declared to her parents that she was going to be a “book lady.” With a life lived in service of reading, it is easy to understand Joan's concern when she was diagnosed with a rare eye condition.